You are here

Entresto

Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group

Novartis’ blockbuster heart med Entresto snags FDA approval in larger patient group

Fierce Pharma

Flag link:

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Novartis' heart failure med Entresto wins FDA panel backing for bigger patient group—but just how much bigger?

Fierce Pharma

heart failure with preserved ejection fraction

Flag link:

ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one

ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one

Fierce Pharma

Flag link:

Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop

Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop

Fierce Pharma

Flag link:

AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata

AHA: Novartis hoping for second go at broader use with 'profound' Entresto subdata

Fierce Pharma

Flag link:

ESC: Novartis looks for the bright side in flopped Entresto heart failure study

ESC: Novartis looks for the bright side in flopped Entresto heart failure study

Fierce Pharma

clinical trials

European Society of Cardiology

Flag link:

5 Reasons Novartis Shareholders Aren't Shaken

5 Reasons Novartis Shareholders Aren't Shaken

Yahoo/Motley Fool

Flag link:

Novartis heart drug fails trial, curbing growth prospects

Novartis heart drug fails trial, curbing growth prospects

Yahoo/Reuters

clinical trials

Flag link:

American College of Cardiology Conference Roundup - day 1

American College of Cardiology Conference Roundup - day 1

CP Wire

American College of Cardiology

Edwards Lifesciences

clinical trials

atrial fibrillation

Flag link:

American College of Cardiology Conference Roundup - day 1

American College of Cardiology

Edwards Lifesciences

clinical trials

atrial fibrillation

Flag link:

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Endpoints

Flag link:

Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto

Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto

NASDAQ.com

Flag link:

One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology

One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology

Fierce Pharma

Flag link:

After a slow start, Novartis finally gains market traction with heart drug Entresto

After a slow start, Novartis finally gains market traction with heart drug Entresto

Fierce Biotech

Flag link:

Drugmakers face challenges marketing new heart drugs

Drugmakers face challenges marketing new heart drugs

Medical Marketing and Media

Flag link:

Novartis set to ride Entresto wave, says report

Novartis set to ride Entresto wave, says report

BioPharma Dive

Flag link:

How Novartis Is Aiming to Increase Entresto Sales in 2017

How Novartis Is Aiming to Increase Entresto Sales in 2017

Market Realist

Flag link:

What Could Boost Medicare Demand for Novartis’s Entresto?

What Could Boost Medicare Demand for Novartis’s Entresto?

Market Realist

Flag link:

Novartis Heart Failure Drug Beats Enalapril

Novartis Heart Failure Drug Beats Enalapril

Investopedia

Flag link:

Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis

Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis

Fierce Pharma

Flag link:

Pages